KNSAのチャート
KNSAの企業情報
| symbol | KNSA |
|---|---|
| 会社名 | Kiniksa Pharmaceuticals Ltd （キニクサ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 キニクサ・ファーマシューティカルズ（Kiniksa Pharmaceuticals Ltd.）は臨床段階のバイオ医薬品会社である。同社は衰弱性疾患に罹患している患者に使用される治療薬の発見、獲得、開発及び商業化に従事する。同社のプログラムには、リロナセプト、マブリリムマブ、KPL-716、KPL-045、KPL-404がある。リロナセプトは、ンターロイキン-1α及びインターロイキン-1βを阻害するタンパク質である。マブリリムマブは、顆粒球マクロファージコロニー刺激因子またはGM-CSFのシグナル伝達に拮抗するモノクローナル抗体である。KPL-716は、それらの共通の受容体サブユニット、オンコスタチンM受容体ベータ、またはOSMRベータを標的とすることによって、インターロイキン31またはIL-31、及びオンコスタチンMまたはOSMのサイトカインのシグナル伝達を同時に阻害するモノクローナル抗体である。KPL-045は、CD30/CD30L相互作用のモノクローナル抗体インヒビターであり、活性化T-メモリー細胞機能に関与するT細胞共刺激レセプターである。KPL-404は、T細胞依存性のB細胞媒介体液性適応免疫の中央制御ノードである。 キニクサ・ファ―マシュ―ティカルズはバミュ―ダ諸島籍のバイオ医薬品企業。有効な治療法が確立されていない衰弱性疾患の治療薬の発見、開発および商品化に焦点を当て事業を行う。主に自己炎症性および自己免疫性疾患の治療薬の臨床試験を手掛ける。主要製品候補には、再発性心膜炎の治療薬Rilonaceptや、巨細胞性動脈炎の治療薬Mavrilimumabなどがある。 Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa's portfolio of assets, ARCALYST, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. |
| 本社所在地 | Clarendon House 2 Church Street Hamilton HM11 BMU |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 441-781439-9100 |
| 設立年月日 | 42186 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 47人 |
| url | www.kiniksa.com |
| nasdaq_url | https://www.nasdaq.com/symbol/knsa |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -86.79100 |
| 終値（lastsale） | 20.46 |
| 時価総額（marketcap） | 1011842384.52 |
| 時価総額 | 時価総額（百万ドル） 1102.344 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 743.15400 |
| 当期純利益 | 当期純利益（百万ドル） -84.90100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Kiniksa Pharmaceuticals Ltd revenues was not reported. Net loss increased from $16.1M to $36.2M. Higher net loss reflects Research and development - Balancing val increase from $12.4M to $29.3M (expense) General and administrative - Balancing v increase of 81% to $7M (expense) Stock-based Compensation in General and increase from $168K to $1.1M (expense). |
KNSAのテクニカル分析
KNSAのニュース
Investing in Kiniksa Pharmaceuticals Ltd. (KNSA) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/02 13:08:00 US Post News
In Tuesday’s session, Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) marked $12.80 per share, up from $11.42 in the previous session. While Kiniksa Pharmaceuticals Ltd. has overperformed by 12.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KNSA rose by 0.55%, with highs and lows ranging from $15.24 to […]
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript 2022/11/01 18:45:24 Seeking Alpha
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:NASDAQ:KNSA) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.
Kiniksa Pharmaceuticals, Ltd. 2022 Q3 - Results - Earnings Call Presentation 2022/11/01 14:31:42 Seeking Alpha
The following slide deck was published by Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals GAAP EPS of $3.18, revenue of $99.13M 2022/11/01 12:44:33 Seeking Alpha
Kiniksa Pharmaceuticals press release (KNSA): Q3 GAAP EPS of $3.18.Revenue of $99.13M (+719.9% Y/Y).Total revenue for the third quarter of 2022 included $33.4 million in ARCALYST…
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update 2022/11/01 12:00:00 GlobeNewswire
– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p<0.0001) – – KPL-404 Phase 2 data in rheumatoid arthritis expected in 1H 2024 – – Cash reserves of $200.7 million expected to fund operations into at least 2025 – – Conference call and webcast scheduled for 8:30 am ET today –
Investing in Kiniksa Pharmaceuticals Ltd. (KNSA) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/02 13:08:00 US Post News
In Tuesday’s session, Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) marked $12.80 per share, up from $11.42 in the previous session. While Kiniksa Pharmaceuticals Ltd. has overperformed by 12.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, KNSA rose by 0.55%, with highs and lows ranging from $15.24 to […]
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript 2022/11/01 18:45:24 Seeking Alpha
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:NASDAQ:KNSA) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.
Kiniksa Pharmaceuticals, Ltd. 2022 Q3 - Results - Earnings Call Presentation 2022/11/01 14:31:42 Seeking Alpha
The following slide deck was published by Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals GAAP EPS of $3.18, revenue of $99.13M 2022/11/01 12:44:33 Seeking Alpha
Kiniksa Pharmaceuticals press release (KNSA): Q3 GAAP EPS of $3.18.Revenue of $99.13M (+719.9% Y/Y).Total revenue for the third quarter of 2022 included $33.4 million in ARCALYST…
Kiniksa Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update 2022/11/01 12:00:00 GlobeNewswire
– ARCALYST ® (rilonacept) Q3 2022 net revenue of $33.4 million – – RHAPSODY long-term extension data demonstrated rilonacept treatment beyond 18 months resulted in continued treatment response (Hazard Ratio = 0.018, p<0.0001) – – KPL-404 Phase 2 data in rheumatoid arthritis expected in 1H 2024 – – Cash reserves of $200.7 million expected to fund operations into at least 2025 – – Conference call and webcast scheduled for 8:30 am ET today –
Kiniksa files for $400M mixed shelf offering (NASDAQ:KNSA) 2022/05/06 20:55:57 Seeking Alpha
Kiniksa Pharmaceuticals (KNSA) has filed for a $400M mixed shelf offering.The filing does not necessarily indicate that a sale has begun, or will occur in the future.
Kiniksa Pharmaceuticals GAAP EPS of -$0.36 misses by $0.03, revenue of $32.18M (NASDAQ:KNSA) 2022/05/03 12:18:11 Seeking Alpha
Kiniksa Pharmaceuticals press release (KNSA): Q1 GAAP EPS of -$0.36 misses by $0.03.Revenue of $32.18M.
Earnings Scheduled For May 3, 2022 2022/05/03 08:52:35 Benzinga
Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ: KNSA ) is projected to report earnings for its first quarter. • Great Lakes Dredge & Dock (NASDAQ: GLDD ) is likely to report quarterly earnings at $0.16 per share on revenue of $170.53 million. • Enel Chile (NYSE: ENIC ) is expected to report quarterly earnings at $82.88 per share on revenue of $994.35 million. • Paramount Global (NASDAQ: PARAA ) is likely to report quarterly earnings at $0.52 per share on revenue of $7.38 billion. • Triton International (NYSE: TRTN ) is likely to report quarterly earnings at $2.63 per share on revenue of $419.07 million. • Colliers Intl Gr (NASDAQ: CIGI ) is likely to report quarterly earnings at $1.59 per share on revenue of $1.14 billion. • Comstock Mining (AMEX: LODE ) is projected to report quarterly loss at $0.03 per share on revenue of $380.00 thousand. • GEO Group (NYSE: GEO ) is expected to report quarterly earnings at $0.22 per share on revenue of $551.47 million. • Kopin (NASDAQ: KOPN ) is expected to report quarterly loss at $0.
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022 2022/05/02 20:01:00 GlobeNewswire
HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. Eastern Time to report its first quarter 2022 financial results and corporate activities.
Greenberg Traurig Represents Huadong Medicine in Two Licensing Deals Totalling Over $1.6 Billion in Value 2022/03/04 01:10:00 Benzinga
ATLANTA , March 3, 2022 /PRNewswire-PRWeb/ -- Wayne H. Elowe , co-chair of the Life Sciences and Medical Technology Group at global law firm Greenberg Traurig, LLP and co-chair of the firm''s Atlanta Corporate Practice, led the Greenberg Traurig team representing Huadong Medicine Co., Ltd., one of the leading pharmaceutical companies in China with a focus on oncology and Antibody-drug Conjugates research, development, and commercialization, on two large licensing deals, both of which closed in February 2022 . These deals mark the continuation of a longstanding relationship between Huadong Medicine and Greenberg Traurig Shareholders Elowe and Dawn (Dan) Zhang ( Shanghai ) who have represented Huadong in numerous transactions. In the first deal, Elowe advised Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of Huadong Medicine , in a strategic collaboration with Kiniksa Pharmaceuticals, Ltd., a U.S. biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, to develop …